ClinicalTrials.gg
Not yet recruitingNCT06918743Updated Apr 9, 2025

To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study

A Phase 2 interventional study of RSS0393 ointment and RSS0393 ointment in Psoriatic Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of RSS0393 ointment in patients with plaque psoriasis Phase II study

02

Conditions studied

  • Psoriatic Subjects
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of signing the must be ≥18 years old and ≤75 years old, male or female
  2. At screening, [BMI= weight (kg)/height 2 (m2)]≥18.0kg/m2
  3. A history of plaque psoriasis ≥6 months prior to randomization
  4. At screening and baseline, the BSA of the affected area was 2%-20% (including both ends), PASI score ≥2, PGA score ≥2.
  5. The subject voluntarily signs informed consent before the start of any procedures related to the study, is able to communicate with the investigator smoothly, understands and is willing to complete the study in strict compliance with the requirements of the clinical study protocol;
  6. A fertile female subject or a male subject whose partner is a fertile woman who has not had a child, plans to donate sperm/eggs from the date of signing the informed consent to 8 weeks after the last dose, and voluntarily uses highly effective methods

Exclusion criteria

Exclusion Criteria:

  1. Present with any of the following medical history or concomitant diseases:

    1. Diagnosis of other types of psoriasis other than plaque psoriasis during subject screening, Such as guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, articular psoriasis, or drug-induced psoriasis
    2. the subject has other skin diseases or conditions that the investigator determines may affect the evaluation of the relevant endpoint of this study
    3. any other persistent active disease, Including but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma or polymyositis, multiple sclerosis or other central demyelinating diseases, primary Sjogren's syndrome, immune deficiency syndromes (such as Felty's syndrome);
  2. There are the following important medical history or underlying diseases that affect safe

    1. The subject has a history of any active or malignancy in the 5 years prior to the screening visit, except skin squamous cell carcinoma or basal cell carcinoma or cervical cancer in situ that has been cured after treatment;
    2. Participants with a history of depression and/or who were clinically deemed to be at risk of suicide during the screening and baseline periods;
    3. Active infection within 2 weeks prior to baseline requiring systemic anti-infective therapy, or severe infection or systemic infection within 4 weeks prior to baseline requiring intravenous anti-infective therapy or hospitalization due to infection, or other chronic, recurrent, or active infections deemed by the investigator not suitable for participation in the study;
    4. had any surgery within 1 month prior to screening, or had not recovered as determined by the investigator, or planned any surgery during the study period;
    5. Currently has an active tuberculosis infection, or chest radiography indicates the presence of an active tuberculosis infection;
    6. any serious, progressive, uncontrolled cardiovascular or cerebrovascular, respiratory, liver, kidney, gastrointestinal, blood, neurological, or psychiatric disorders, or medical measures, medical conditions, etc. that may affect study participation, or may place subjects at undue risk, as determined by the investigator;
  3. At the time of screening, laboratory tests and/or 12-lead showed the following:

    1. \< 100.0 g/L (male) or \< 90.0 g/L (female);
    2. White blood cell count \< 3.0×109/L;
    3. \< 1.5×109/L;
    4. count \< 100×109/L;
    5. (ALT) or aspartate aminotransferase (AST) > 2.5 times the (ULN);
    6. Total (TBIL) > 1.5 times the upper limit of normal (ULN); g) The estimated (eGFR) calculated by the simplified MDRD formula (see Appendix 13.5 for details) is \< 60 mL/min/1.73 m², or the serum creatinine is outside the normal range, and the investigator determines that participation in this study is not appropriate;
    7. surface antigen (HBsAg), antibody (HIV), syphilis antibody test, anti- virus (HCV) antibody test positive; If HBsAg is negative but hepatitis B core antibody (HBcAb) positive and hepatitis B virus deoxyribonucleic acid (HBV DNA) positive or above the upper limit of normal;
    8. 12-lead electrocardiogram examination indicates abnormalities that may affect the safety of the subject, including but not limited to acute myocardial ischemia, myocardial infarction, severe arrhythmia, or significant prolongation (QTc>500 ms).
  4. General situation

    1. Pregnant or lactating women, defined as the female state from pregnancy to termination of pregnancy and positive blood test for human chorionic gonadotropin (β-HCG) during the screening period;
    2. Allergic to the drug or any ingredient in the investigational drug
    3. a history of alcohol or illicit drug abuse in the year prior to screening
    4. received a in the 12 weeks prior to randomization, intended to receive a live attenuated vaccine during the study period, or participated in a vaccine clinical trial in the 12 weeks prior to randomization
    5. Donate approximately 500 mL blood within 8 weeks prior to randomization or have a blood donation plan during the study period
    6. Subjects who are expected to have excessive exposure to natural/artificial light, sunbathing, or other light emitting diodes (leds) in the treatment area during treatment in this study; The investigators determined that there were conditions that affected the safety and efficacy evaluation of the study drugs or other conditions that were not suitable for inclusion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (estimated)

Study arms

  • Experimental
    Treatment group 1

    RSS0393 ointment 0.01%

    Drug: RSS0393 ointment

  • Experimental
    Treatment group 2

    RSS0393 ointment 0.03%

    Drug: RSS0393 ointment

  • Placebo comparator
    Treatment group 3

    RSS0393 ointment placebo

    Drug: RSS0393 ointment placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a clinician's overall assessment (PGA) response (defined as a PGA score of 0 (clear) or 1 (nearly clear) with ≥2 points improvement from baseline)

    Time frame: 8weeks

Secondary outcomes

  1. Proportion of participants who achieved at least 75% improvement (PASI 75) from baseline;

    Time frame: 14weeks

  2. The proportion of subjects with PGA response at each visit

    Time frame: 14weeks

  3. Absolute and percentage changes in PASI scores at each visit compared to baseline;

    Time frame: 14weeks

  4. The proportion of subjects who achieved PGA 0 or 1 score at each visit

    Time frame: 14weeks

  5. The time of the subject reached PASI 50 within 12 weeks

    Time frame: 14weeks

  6. The proportion of participants who achieved at least a 50% improvement (PASI 50) in PASI scores from baseline at each visit

    Time frame: 14weeks

  7. Percentage of participants who achieved at least a 90% improvement (PASI 90) from baseline in PASI scores at each visit

    Time frame: 14weeks

  8. Absolute and percentage changes in the most intense itch digital score (WI-NRS) from baseline at each visit ;

    Time frame: 14weeks

  9. The proportion of subjects with baseline involvement in the intererase area and intererase PGA (I-PGA) score ≥2 who achieved an I-PGA response (defined as an I-PGA of 0 or 1 with ≥2 points improvement from baseline) at each visit

    Time frame: 14weeks

  10. The proportion of subjects with baseline involvement and I-PGA score ≥2 who achieved I-PGA score 0 at each visit

    Time frame: 14weeks

  11. Absolute value of change in skin quality of life index (DLQI) from baseline at each visit

    Time frame: 14weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Mar 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 9, 2025
StartEst.
Apr 2025
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06918743
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Apr 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Apr 9, 2025

Study contacts

Shuang Li
Contact
Shuang.li.sl100@hengrui.com
18604031725

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RSS0393

Start the discussion